Compare TRVG & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | BNTC |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.1M | 405.7M |
| IPO Year | N/A | N/A |
| Metric | TRVG | BNTC |
|---|---|---|
| Price | $2.87 | $12.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $3.96 | ★ $27.67 |
| AVG Volume (30 Days) | 45.2K | ★ 218.1K |
| Earning Date | 02-03-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $614,486,683.00 | N/A |
| Revenue This Year | $18.36 | N/A |
| Revenue Next Year | $9.18 | N/A |
| P/E Ratio | $96.11 | ★ N/A |
| Revenue Growth | ★ 14.41 | N/A |
| 52 Week Low | $2.21 | $9.70 |
| 52 Week High | $5.83 | $17.15 |
| Indicator | TRVG | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 44.49 |
| Support Level | $2.79 | $11.21 |
| Resistance Level | $2.93 | $14.39 |
| Average True Range (ATR) | 0.10 | 1.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 23.29 | 48.88 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.